HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Roger L White Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by White, R. L Search for Related Content PubMed Articles by White, R. L

Thrombolytic Therapy in Acute Myocardial Infarction Part II: 1997 Update

Department of Cardiology Straub Clinic and Hospital Honolulu, Hawaii, USA

Roger L White, MD Department of Cardiology Straub Clinic and Hospital 888 South King Street Honolulu, HI 96813, USA Tel:1 808 522 4222 Fax:1 808 522 4065

Thrombolytic therapy has become an established treatment for acute myocardial infarction. Streptokinase was first demonstrated in 1988 to reduce mortality rates. In 1993, tissue plasminogen activator was shown to have a slight superiority over streptokinase in reducing mortality rates (approximately 1%). Reteplase is a second generation thrombolytic agent that is given in two bolus injections intravenously over 30 minutes. Studies demonstrated slightly better and more rapid improvement in myocardial perfusion with reteplase compared to tissue plasminogen activator. However, recent studies showed 30-day mortality rates in patients treated with reteplase were similar as those treated with tissue plasminogen activator. The use of angioplasty, aspirin, beta blockers, angiotensin converting enzyme inhibitors, and lipid lowering agents also contribute to the reduction of mortality from acute myocardial infarction.